Physician profile
Edward Farley
NPI 1750475331
$434.26
in general payments reported to CMS, 2019-2025
13 companies · $74.27 in 2025
The $74.27 reported for 2025 was less than what a typical Diagnostic Radiology provider received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.88 · 2020: $25.00 · 2021: $21.60 · 2022: $77.19 · 2023: $113 · 2024: $36.03 · 2025: $74.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $223.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $100.09 | 2023 | Pylarify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.88 | 2019 | |
| Merck Sharp & Dohme LLC | $39.32 | 2022 | |
| Genentech USA, INC. | $28.80 | 2024-2025 | Phesgo, Tecentriq |
| Tersera Therapeutics LLC | $26.70 | 2025 | Quzyttir |
| Stryker Corporation | $25.00 | 2020 | |
| Daiichi Sankyo INC. | $22.40 | 2024 | Injectafer |
| Siemens Medical Solutions USA, INC. | $21.60 | 2021 | |
| Eisai INC. | $20.28 | 2022 | |
| Genzyme Corporation | $17.59 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.51 | 2025 | Fruzaqla |
| Novocure INC. | $15.89 | 2025 | Optune Lua (Novottf-200t) |
| Mirati Therapeutics, INC. | $13.20 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Farley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.